{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:34:42Z","timestamp":1792704882020,"version":"4.5.0"},"reference-count":229,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Gastrointestinal malignant tumors exhibit a high incidence and mortality rate among all malignancies worldwide, making them a significant concern within the field of oncology. Targeted therapy for gastrointestinal tumors has become a hot topic in recent years, and its specific mechanism remains to be further elucidated. Secreted factors, including cytokines, chemokines, and growth factors, as components of the tumor microenvironment, play a crucial role in the progression of gastrointestinal tumors. Interferon-gamma (IFN-\u03b3) can activate these factors through JAK1\/2 and STAT1 signaling (the IFN-\u03b3\/STAT1 pathway). This pathway is considered \u201ca double-edged sword\u201d and maintains a dual role in promoting or inhibiting tumor progression by activating different downstream factors. In this review, we summarize the functions, mechanisms, and key factors of the IFN-\u03b3\/STAT1 pathway that promote or inhibit gastrointestinal tumor progression and discuss therapeutic prospects for targets of the pathway.<\/jats:p>","DOI":"10.3389\/fonc.2025.1598170","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T04:15:01Z","timestamp":1755663301000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Dual regulation of gastrointestinal tumor progression by the IFN-\u03b3\/STAT1 pathway and prospects for targeted therapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuhao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00366-7","article-title":"Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: A population-based systematic analysis of Globocan","volume":"9","author":"Wang","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00726-3","article-title":"Updated epidemiology of gastrointestinal cancers in east Asia","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-2667(18)30267-6","article-title":"Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry","volume":"4","author":"Sung","year":"2019","journal-title":"Lancet Public Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA: Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5418","article-title":"Comparison of characteristics and outcomes of young-onset versus average onset pancreatico-biliary adenocarcinoma","volume":"12","author":"Jayakrishnan","year":"2023","journal-title":"Cancer Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-22-1038","article-title":"Early-onset cancer in the gastrointestinal tract is on the rise-evidence and implications","volume":"13","author":"Ben-Aharon","year":"2023","journal-title":"Cancer Discov"},{"key":"B9","article-title":"Cellular location of carcinoembryonic antigens of the human digestive system","volume":"28","author":"Gold","year":"1968","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.122.3.467","article-title":"Specific carcinoembryonic antigens of the human digestive system","volume":"122","author":"Gold","year":"1965","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"101280","DOI":"10.1016\/j.smim.2019.05.002","article-title":"Ifn-\u0393: A cytokine at the right time, is in the right place","volume":"43","author":"Burke","year":"2019","journal-title":"Semin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41586-019-0988-7","article-title":"Structure of the Ifn\u03b3 Receptor complex guides design of biased agonists","volume":"567","author":"Mendoza","year":"2019","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0029-z","article-title":"Ifn\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028423","article-title":"The interferon (Ifn) class of cytokines and the Ifn regulatory factor (Irf) transcription factor family","volume":"10","author":"Negishi","year":"2018","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-19-0083","article-title":"Ifn\u03b3, a double-edged sword in cancer immunity and metastasis","volume":"79","author":"Liu","year":"2019","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cytogfr.2016.07.005","article-title":"The untold story of Ifn-\u0393 in cancer biology","volume":"31","author":"Kursunel","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol: CB"},{"key":"B18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.gastro.2013.03.052","article-title":"The gastrointestinal tumor microenvironment","volume":"145","author":"Quante","year":"2013","journal-title":"Gastroenterology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-013-0645-9","article-title":"Immune system: A double-edged sword in cancer","volume":"62","author":"Lakshmi Narendra","year":"2013","journal-title":"Inflammation Res: Off J Eur Histamine Res Soc"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090400","article-title":"The Irf family transcription factors in immunity and oncogenesis","volume":"26","author":"Tamura","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0962-8924(00)01906-1","article-title":"Integrin-associated protein (Cd47) and its ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.60782","article-title":"Cd47\/Sirp\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101162","article-title":"Regulation of Cd47 expression by interferon-gamma in cancer cells","volume":"14","author":"Ye","year":"2021","journal-title":"Trans Oncol"},{"key":"B25","article-title":"Pd-1\/Pd-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0000000000000061","article-title":"Inducible expression of B7-H1 (Pd-L1) and its selective role in tumor site immune modulation","volume":"20","author":"Sanmamed","year":"2014","journal-title":"Cancer J (Sudbury Mass)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific Cd8 T cells infiltrating the tumor express high levels of Pd-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111057","article-title":"Triptolide suppresses oral cancer cell Pd-L1 expression in the interferon-\u0393-modulated microenvironment in vitro, in vivo, and in clinical patients","volume":"133","author":"Kuo","year":"2021","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12203","article-title":"Mage-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma","volume":"41","author":"Wu","year":"2021","journal-title":"Cancer Commun (London England)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"17810","DOI":"10.1038\/s41598-017-18132-0","article-title":"Ifn\u03b3 Induces Pd-L1 overexpression by Jak2\/Stat1\/Irf-1 signaling in Ebv-positive gastric carcinoma","volume":"7","author":"Moon","year":"2017","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2019.02.038","article-title":"Ifn-\u0393 Promotes epithelial-mesenchymal transition and the expression of Pd-L1 in pancreatic cancer","volume":"240","author":"Imai","year":"2019","journal-title":"J Surg Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s40425-019-0784-9","article-title":"Ezh2 negatively regulates Pd-L1 expression in hepatocellular carcinoma","volume":"7","author":"Xiao","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11647","article-title":"Pd-L1 expression increased by Ifn-\u0393 Via Jak2-Stat1 signaling and predicts a poor survival in colorectal cancer","volume":"20","author":"Zhao","year":"2020","journal-title":"Oncol Lett"},{"key":"B34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","article-title":"Pd-L1 expression is mainly regulated by interferon gamma associated with Jak-Stat pathway in gastric cancer","volume":"109","author":"Mimura","year":"2018","journal-title":"Cancer Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-023-01900-0","article-title":"Acidosis-mediated increase in Ifn-\u0393-induced Pd-L1 expression on cancer cells as an immune escape mechanism in solid tumors","volume":"22","author":"Knopf","year":"2023","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-021-01547-3","article-title":"Interferon gamma-induced interferon regulatory factor 1 activates transcription of Hhla2 and induces immune escape of hepatocellular carcinoma cells","volume":"45","author":"Wang","year":"2022","journal-title":"Inflammation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13046-019-1186-z","article-title":"Mtmr2 promotes invasion and metastasis of gastric cancer via inactivating Ifn\u03b3\/Stat1 signaling","volume":"38","author":"Jiang","year":"2019","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-Dioxygenase 1 (Ido1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1185985","article-title":"Abrine, an Ido1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-pd-1 antibody in hepatocellular carcinoma","volume":"14","author":"Liang","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15207","article-title":"Blockade of Ido-Kynurenine-Ahr metabolic circuitry abrogates Ifn-\u0393-induced immunologic dormancy of tumor-repopulating cells","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s42003-020-0989-y","article-title":"Ido1(+) paneth cells promote immune escape of colorectal cancer","volume":"3","author":"Pfl\u00fcgler","year":"2020","journal-title":"Commun Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1007532","DOI":"10.1371\/journal.ppat.1007532","article-title":"Interferon-induced transmembrane protein 3 blocks fusion of sensitive but not resistant viruses by partitioning into virus-carrying endosomes","volume":"15","author":"Suddala","year":"2019","journal-title":"PloS Pathog"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2525","article-title":"Enhanced survival of lung tissue-resident memory Cd8+ T cells during infection with influenza virus due to selective expression of Ifitm3","volume":"14","author":"Wakim","year":"2013","journal-title":"Nat Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-10-2729","article-title":"Klf4-mediated negative regulation of Ifitm3 expression plays a critical role in colon cancer pathogenesis","volume":"17","author":"Li","year":"2011","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41467-023-44391-9","article-title":"Foxp3(+) regulatory T cell perturbation mediated by the Ifn\u03b3-Stat1-Ifitm3 feedback loop is essential for anti-tumor immunity","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/rheumatology\/keaa609","article-title":"Interferon-stimulated Gtpases in autoimmune and inflammatory diseases: promising role for the guanylate-binding protein (Gbp) family","volume":"60","author":"Haque","year":"2021","journal-title":"Rheumatol (Oxford England)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/science.1217141","article-title":"Gbp5 promotes Nlrp3 inflammasome assembly and immunity in mammals","volume":"336","author":"Shenoy","year":"2012","journal-title":"Sci (New York NY)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-021-00672-3","article-title":"Limit is an immunogenic Lncrna in cancer immunity and immunotherapy","volume":"23","author":"Li","year":"2021","journal-title":"Nat Cell Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41419-021-03492-3","article-title":"Gbp5 drives Malignancy of glioblastoma via the Src\/Erk1\/2\/Mmp3 pathway","volume":"12","author":"Yu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9040371","article-title":"Gbp5 repression suppresses the metastatic potential and Pd-L1 expression in triple-negative breast cancer","volume":"9","author":"Cheng","year":"2021","journal-title":"Biomedicines"},{"key":"B51","article-title":"Guanylate binding protein 5 accelerates gastric cancer progression via the Jak1-Stat1\/Gbp5\/Cxcl8 positive feedback loop","volume":"13","author":"Cao","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"eabj0486","DOI":"10.1126\/science.abj0486","article-title":"Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis","volume":"373","author":"Del Poggetto","year":"2021","journal-title":"Sci (New York NY)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11061195","article-title":"The breast cancer protooncogenes Her2, Brca1 and Brca2 and their regulation by the Inos\/Nos2 axis","volume":"11","author":"Lin","year":"2022","journal-title":"Antioxid (Basel Switzerland)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: A review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J Cell Physiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.7510419","article-title":"Requirement for transcription factor Irf-1 in no synthase induction in macrophages","volume":"263","author":"Kamijo","year":"1994","journal-title":"Sci (New York NY)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.12.2131","article-title":"Interferon regulatory factor (Irf)-1 and Irf-2 regulate interferon gamma-dependent cyclooxygenase 2 expression","volume":"191","author":"Blanco","year":"2000","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/35094017","article-title":"Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2","volume":"1","author":"Gupta","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1046","article-title":"Radical causes of cancer","volume":"3","author":"Hussain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20060436","article-title":"Ifngamma-dependent, spontaneous development of colorectal carcinomas in Socs1-deficient mice","volume":"203","author":"Hanada","year":"2006","journal-title":"J Exp Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.191031","article-title":"Up-regulation and sustained activation of Stat1 are essential for interferon-gamma (Ifn-gamma)-induced dual oxidase 2 (Duox2) and dual oxidase A2 (Duoxa2) expression in human pancreatic cancer cell lines","volume":"286","author":"Wu","year":"2011","journal-title":"J Biol Chem"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1172\/jci141676","article-title":"Duox2 variants associate with preclinical disturbances in microbiota-immune homeostasis and increased inflammatory bowel disease risk","volume":"131","author":"Grasberger","year":"2021","journal-title":"J Clin Invest"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/s0079-6603(02)71043-x","article-title":"Muc4\/sialomucin complex, the intramembrane Erbb2 ligand, in cancer and epithelia: to protect and to survive","volume":"71","author":"Carraway","year":"2002","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-08-2089","article-title":"The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via Erbb2-dependent and Erbb2-independent mechanisms","volume":"69","author":"Workman","year":"2009","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.Mcr-06-0353","article-title":"Muc4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins","volume":"5","author":"Chaturvedi","year":"2007","journal-title":"Mol Cancer Res: MCR"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-06-3114","article-title":"Emerging roles of Muc4 in cancer: A novel target for diagnosis and therapy","volume":"67","author":"Singh","year":"2007","journal-title":"Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M104204200","article-title":"Characterization of human mucin gene muc4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells","volume":"276","author":"Perrais","year":"2001","journal-title":"J Biol Chem"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602163","article-title":"Multiple roles of mucins in pancreatic cancer, a lethal and challenging Malignancy","volume":"91","author":"Moniaux","year":"2004","journal-title":"Br J Cancer"},{"key":"B69","article-title":"Mucin (Muc) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: A potential role of muc4 as a tumor marker of diagnostic significance","volume":"7","author":"Andrianifahanana","year":"2001","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-03-2636","article-title":"Inhibition of Muc4 expression suppresses pancreatic tumor cell growth and metastasis","volume":"64","author":"Singh","year":"2004","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1126\/science.7690989","article-title":"A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma","volume":"261","author":"Shuai","year":"1993","journal-title":"Sci (New York NY)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210532","article-title":"Ifn-gamma-induced expression of muc4 in pancreatic cancer cells is mediated by Stat-1 upregulation: A novel mechanism for Ifn-gamma response","volume":"26","author":"Andrianifahanana","year":"2007","journal-title":"Oncogene"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/107999002753452610","article-title":"Activities of Irf-1","volume":"22","author":"Kr\u00f6ger","year":"2002","journal-title":"J Interferon Cytokine Res: Off J Int Soc Interferon Cytokine Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-07-5021","article-title":"Negative feedback regulation of Ifn-gamma pathway by Ifn regulatory factor 2 in esophageal cancers","volume":"68","author":"Wang","year":"2008","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i42.4738","article-title":"Cxc family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer","volume":"24","author":"Cabrero-de Las Heras","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e0176994","DOI":"10.1371\/journal.pone.0176994","article-title":"Stat2 is involved in the pathogenesis of psoriasis by promoting Cxcl11 and Ccl5 production by keratinocytes","volume":"12","author":"Johansen","year":"2017","journal-title":"PloS One"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.61.3.246","article-title":"Mig and Ip-10: Cxc chemokines that target lymphocytes","volume":"61","author":"Farber","year":"1997","journal-title":"J Leuk Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.4.2278","article-title":"Cxc chemokine ligand 9\/monokine induced by Ifn-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors","volume":"178","author":"Gorbachev","year":"2007","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B79","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1186\/s13046-022-02564-2","article-title":"Cyclin G2 in macrophages triggers Ctl-mediated antitumor immunity and antiangiogenesis via interferon-gamma","volume":"41","author":"Liu","year":"2022","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.6169","article-title":"Epithelial mesenchymal transition induced by the Cxcl9\/Cxcr3 axis through Akt activation promotes invasion and metastasis in tongue squamous cell carcinoma","volume":"39","author":"Li","year":"2018","journal-title":"Oncol Rep"},{"key":"B81","article-title":"Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo","volume":"142","author":"Ohmori","year":"1993","journal-title":"Am J Pathol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.2337\/db06-0477","article-title":"Modular activation of nuclear factor-kappab transcriptional programs in human diabetic nephropathy","volume":"55","author":"Schmid","year":"2006","journal-title":"Diabetes"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"Cxcl9, Cxcl10, Cxcl11\/Cxcr3 axis for immune activation - a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e26264","DOI":"10.1371\/journal.pone.0026264","article-title":"Loss of the promyelocytic leukemia protein in gastric cancer: implications for Ip-10 expression and tumor-infiltrating lymphocytes","volume":"6","author":"Kim","year":"2011","journal-title":"PloS One"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.032","article-title":"Cxcl10\/Cxcr3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation","volume":"65","author":"Li","year":"2016","journal-title":"J Hepatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.08.017","article-title":"Post-transplant endothelial progenitor cell mobilization via Cxcl10\/Cxcr3 signaling promotes liver tumor growth","volume":"60","author":"Ling","year":"2014","journal-title":"J Hepatol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/moh.0000000000000389","article-title":"The regulation and importance of monocyte chemoattractant protein-1","volume":"25","author":"Bianconi","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (Mcp-1): an overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J Interferon Cytokine Res: Off J Int Soc Interferon Cytokine Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17060868","article-title":"Role of matrix metalloproteinases in photoaging and photocarcinogenesis","volume":"17","author":"Pittayapruek","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007624","article-title":"Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-Ccl2-mediated immunity","volume":"11","author":"Bhoopathi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.2174\/0929867043364748","article-title":"Tachykinins and tachykinin receptors: structure and activity relationships","volume":"11","author":"Almeida","year":"2004","journal-title":"Curr Med Chem"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091258","article-title":"Neurokinin-1 receptor antagonists against hepatoblastoma","volume":"11","author":"Mu\u00f1oz","year":"2019","journal-title":"Cancers"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.09.013","article-title":"Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; effects independent of substance P","volume":"108","author":"Nizam","year":"2018","journal-title":"Biomed Pharmacother = Biomed Pharmacother"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2009.03.006","article-title":"Neurokinin 1 receptor isoforms and the control of innate immunity","volume":"30","author":"Tuluc","year":"2009","journal-title":"Trends Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102521","article-title":"Neuropeptide signaling activates dendritic cell-mediated type 1 immune responses through neurokinin-2 receptor","volume":"188","author":"Kitamura","year":"2012","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15738","article-title":"Ifn-\u0393-Stat1-mediated Nk2r expression is involved in the induction of antitumor effector Cd8(+) T cells in vivo","volume":"114","author":"Shen","year":"2023","journal-title":"Cancer Sci"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)42225-3","article-title":"Ifp 35 is an interferon-induced leucine zipper protein that undergoes interferon-regulated cellular redistribution","volume":"269","author":"Bange","year":"1994","journal-title":"J Biol Chem"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-014-2147-7","article-title":"A critical role of interferon-induced protein Ifp35 in the type I interferon response in cells induced by foot-and-mouth disease virus (Fmdv) protein 2c","volume":"159","author":"Zheng","year":"2014","journal-title":"Arch Virol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.03202-13","article-title":"Interferon-inducible protein Ifi35 negatively regulates rig-I antiviral signaling and supports vesicular stomatitis virus replication","volume":"88","author":"Das","year":"2014","journal-title":"J Virol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12929-023-00930-6","article-title":"Tumor-secreted Ifi35 promotes proliferation and cytotoxic activity of Cd8(+) T cells through Pi3k\/Akt\/Mtor signaling pathway in colorectal cancer","volume":"30","author":"Li","year":"2023","journal-title":"J Biomed Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1172\/jci153167","article-title":"Histone methyltransferase Whsc1 loss dampens Mhc-I antigen presentation pathway to impair Ifn-\u0393-stimulated antitumor immunity","volume":"132","author":"Ren","year":"2022","journal-title":"J Clin Invest"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/nature08086","article-title":"A histone H3 lysine 36 trimethyltransferase links Nkx2\u20135 to Wolf-Hirschhorn syndrome","volume":"460","author":"Nimura","year":"2009","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2011.08.042","article-title":"Nsd2 links dimethylation of histone H3 at lysine 36 to oncogenic programming","volume":"44","author":"Kuo","year":"2011","journal-title":"Mol Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.20080","article-title":"Malignant hematological disorders in children with Wolf-Hirschhorn syndrome","author":"Sharathkumar","year":"2003","journal-title":"Am J Med Genet Part A"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1172\/jci91144","article-title":"Akt-mediated stabilization of histone methyltransferase Whsc1 promotes prostate cancer metastasis","volume":"127","author":"Li","year":"2017","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-18-0451","article-title":"Transcription factor Prox1 suppresses notch pathway activation via the nucleosome remodeling and deacetylase complex in colorectal cancer stem-like cells","volume":"78","author":"H\u00f6gstr\u00f6m","year":"2018","journal-title":"Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12071624","article-title":"The role of prox1 in neoplasia: A key player often overlooked","volume":"12","author":"Ntikoudi","year":"2022","journal-title":"Diagnost (Basel Switzerland)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-92","article-title":"Altered regulation of Prox1-gene-expression in liver tumors","volume":"8","author":"Dudas","year":"2008","journal-title":"BMC Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-06-0712","article-title":"A homeobox protein, Prox1, is involved in the differentiation, proliferation, and prognosis in hepatocellular carcinoma","volume":"12","author":"Shimoda","year":"2006","journal-title":"Clin Cancer Res: an Off J Am Assoc Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1593\/neo.06595","article-title":"Loss of function of the candidate tumor suppressor Prox1 by rna mutation in human cancer cells","volume":"8","author":"Takahashi","year":"2006","journal-title":"Neoplasia (New York NY)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030446","article-title":"Prox1, a key mediator of the anti-proliferative effect of rapamycin on hepatocellular carcinoma cells","volume":"11","author":"Kwon","year":"2022","journal-title":"Cells"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1683-6","article-title":"Transcriptional factor Prox1 plays an essential role in the antiproliferative action of interferon-\u0393 in esophageal cancer cells","volume":"18","author":"Akagami","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41698-023-00407-7","article-title":"Targeting Cdk1 in cancer: mechanisms and implications","volume":"7","author":"Wang","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202189","article-title":"Interaction with cyclin-dependent kinases and pcna modulates proteasome-dependent degradation of P21","volume":"17","author":"Cayrol","year":"1998","journal-title":"Oncogene"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5262.719","article-title":"Cell growth arrest and induction of cyclin-dependent kinase inhibitor P21 Waf1\/Cip1 mediated by stat1","volume":"272","author":"Chin","year":"1996","journal-title":"Sci (New York NY)"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-4652(200007)184:1<131::Aid-jcp14>3.0.Co;2-w","article-title":"Interruption of Nfkappab-Stat1 signaling mediates Egf-induced cell-cycle arrest","volume":"184","author":"Ohtsubo","year":"2000","journal-title":"J Cell Physiol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1089\/107999099312812","article-title":"Ifn-gamma induction of P21(Waf1) is required for cell cycle inhibition and suppression of apoptosis","volume":"19","author":"Hobeika","year":"1999","journal-title":"J Interferon Cytokine Res: Off J Int Soc Interferon Cytokine Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1615\/jenvpathtoxoncol.v22.i3.30","article-title":"C-myc-induced genomic instability","volume":"22","author":"Mai","year":"2003","journal-title":"J Environ Pathol Toxicol Oncol: Off Organ Int Soc Environ Toxicol Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1038\/s41467-019-11662-3","article-title":"Cd36 inhibits B-catenin\/C-myc-mediated glycolysis through ubiquitination of Gpc4 to repress colorectal tumorigenesis","volume":"10","author":"Fang","year":"2019","journal-title":"Nat Commun"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2021.145718","article-title":"Arginine methyltransferase prmt3 promote tumorigenesis through regulating C-myc stabilization in colorectal cancer","volume":"791","author":"Hu","year":"2021","journal-title":"Gene"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.2.263","article-title":"Regulation of C-myc expression by Ifn-gamma through Stat1-dependent and -independent pathways","volume":"19","author":"Ramana","year":"2000","journal-title":"EMBO J"},{"key":"B122","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1349-7006.2006.00137.x","article-title":"Strong Hla-dr antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of C-myc suppression by interferon-gamma in situ","volume":"97","author":"Matsushita","year":"2006","journal-title":"Cancer Sci"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11137","article-title":"Cell death: A review of the major forms of apoptosis, necrosis and autophagy","volume":"43","author":"D\u2019Arcy","year":"2019","journal-title":"Cell Biol Int"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091479","article-title":"Crosstalk of autophagy and apoptosis","volume":"11","author":"Sorice","year":"2022","journal-title":"Cells"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00365-18","article-title":"Pathogenic effects of ifit2 and interferon-B During fatal systemic candida albicans infection","volume":"9","author":"Stawowczyk","year":"2018","journal-title":"mBio"},{"key":"B126","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/jir.2012.0159","article-title":"A death-promoting role for Isg54\/Ifit2","volume":"33","author":"Reich","year":"2013","journal-title":"J Interferon Cytokine Res: Off J Int Soc Interferon Cytokine Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.207068","article-title":"The interferon stimulated gene 54 promotes apoptosis","volume":"286","author":"Stawowczyk","year":"2011","journal-title":"J Biol Chem"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1994.1591","article-title":"Structure, chromosome localization, and regulation of expression of the interferon-regulated mouse Ifi54\/Ifi56 gene family","volume":"24","author":"Bluyssen","year":"1994","journal-title":"Genomics"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.418","article-title":"The lim protein ajuba promotes colorectal cancer cell survival through suppression of Jak1\/Stat1\/Ifit2 network","volume":"36","author":"Jia","year":"2017","journal-title":"Oncogene"},{"key":"B130","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/s0014-4827(02)00011-3","article-title":"Downregulation of P21(Waf\/Cip-1) mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-gamma","volume":"282","author":"Detjen","year":"2003","journal-title":"Exp Cell Res"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-016-0454-1","article-title":"Microbial inhibitors of cysteine proteases","volume":"205","author":"K\u0119dzior","year":"2016","journal-title":"Med Microbiol Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.29.20049","article-title":"Suicidal tendencies: apoptotic cell death by caspase family proteinases","volume":"274","author":"Wolf","year":"1999","journal-title":"J Biol Chem"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-073119-095439","article-title":"Caspases in cell death, inflammation, and pyroptosis","volume":"38","author":"Kesavardhana","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(96)05523-7","article-title":"Pancreatic carcinoma","volume":"349","author":"Rosewicz","year":"1997","journal-title":"Lancet (London England)"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.2.251","article-title":"Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis","volume":"49","author":"Detjen","year":"2001","journal-title":"Gut"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.17.9.5328","article-title":"Activation of the stat signaling pathway can cause expression of caspase 1 and apoptosis","volume":"17","author":"Chin","year":"1997","journal-title":"Mol Cell Biol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.43.30651","article-title":"Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45\/inhibitor of caspase-activated dnase inactivation","volume":"274","author":"Wolf","year":"1999","journal-title":"J Biol Chem"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006988832729","article-title":"Involvement of parp and poly(Adp-ribosyl)Ation in the early stages of apoptosis and DNA replication","volume":"193","author":"Simbulan-Rosenthal","year":"1999","journal-title":"Mol Cell Biochem"},{"key":"B139","article-title":"Specific proteolytic cleavage of poly(Adp-ribose) polymerase: an early marker of chemotherapy-induced apoptosis","volume":"53","author":"Kaufmann","year":"1993","journal-title":"Cancer Res"},{"key":"B140","article-title":"Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate","volume":"56","author":"An","year":"1996","journal-title":"Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb01089.x","article-title":"Specific cleavage of the retinoblastoma protein by an ice-like protease in apoptosis","volume":"15","author":"J\u00e4nicke","year":"1996","journal-title":"EMBO J"},{"key":"B142","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the pathogenesis of disease","volume":"132","author":"Levine","year":"2008","journal-title":"Cell"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/nature06639","article-title":"Autophagy fights disease through cellular self-digestion","volume":"451","author":"Mizushima","year":"2008","journal-title":"Nature"},{"key":"B144","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41419-023-06154-8","article-title":"Autophagy: regulator of cell death","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2011.09.031","article-title":"Interferon-\u0393 Induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (Hcc) cells through interferon-regulatory factor-1 (Irf-1)","volume":"314","author":"Li","year":"2012","journal-title":"Cancer Lett"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.11569\/wcjd.v17.i11.1103","article-title":"Role of Ifn-\u0393-Stat1 pathway in human gastric adenocarcinoma","volume":"17","author":"Deng","year":"2009","journal-title":"Shijie Huaren Xiaohua Zazhi."},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107463","article-title":"Usp36 inhibits apoptosis by deubiquitinating Ciap1 and survivin in colorectal cancer cells","volume":"300","author":"Gao","year":"2024","journal-title":"J Biol Chem"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i7.1013","article-title":"Significance of survivin and Pten expression in full lymph node-examined gastric cancer","volume":"12","author":"Deng","year":"2006","journal-title":"World J Gastroenterol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2011.423","article-title":"The antagonistic effect between Stat1 and survivin and its clinical significance in gastric cancer","volume":"3","author":"Deng","year":"2012","journal-title":"Oncol Lett"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154636","article-title":"The role of interferon-gamma and its receptors in gastrointestinal cancers","volume":"248","author":"Mozooni","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003663","article-title":"Loss of Ythdf1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells","volume":"10","author":"Bai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B152","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.canlet.2006.05.014","article-title":"Deferoxamine enhances anti-proliferative effect of interferon-gamma against hepatocellular carcinoma cells","volume":"248","author":"Okada","year":"2007","journal-title":"Cancer Lett"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2086-8","article-title":"Cross-talk between Tnf-A and Ifn-\u0393 Signaling in induction of B7-H1 expression in hepatocellular carcinoma cells","volume":"67","author":"Li","year":"2018","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B154","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2022.11.018","article-title":"N-glycosylation regulates intrinsic Ifn-\u0393 Resistance in colorectal cancer: implications for immunotherapy","volume":"164","author":"Krug","year":"2023","journal-title":"Gastroenterology"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-1571","article-title":"Loss of optineurin drives cancer immune evasion via palmitoylation-dependent Ifngr1 lysosomal sorting and degradation","volume":"11","author":"Du","year":"2021","journal-title":"Cancer Discov"},{"key":"B156","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13148-018-0589-6","article-title":"Hdac is indispensable for Ifn-\u0393-induced B7-H1 expression in gastric cancer","volume":"10","author":"Deng","year":"2018","journal-title":"Clin Epigenet"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","article-title":"The molecular basis of Jak\/Stat inhibition by Socs1","volume":"9","author":"Liau","year":"2018","journal-title":"Nat Commun"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.Crc-21-0186","article-title":"Small-molecule Ptpn2 inhibitors sensitize resistant melanoma to anti-pd-1 immunotherapy","volume":"3","author":"Zhu","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0315-3","article-title":"Met inhibition revokes Ifn\u03b3-induction of Pd-1 ligands in met-amplified tumours","volume":"120","author":"Martin","year":"2019","journal-title":"Br J Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2018.07.006","article-title":"Myc inhibition increases Pd-L1 expression induced by Ifn-\u0393 in hepatocellular carcinoma cells","volume":"101","author":"Zou","year":"2018","journal-title":"Mol Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12929-021-00769-9","article-title":"Proteasome inhibitors restore the Stat1 pathway and enhance the expression of Mhc class I on human colon cancer cells","volume":"28","author":"Liang","year":"2021","journal-title":"J Biomed Sci"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16902","article-title":"Erk expression and its correlation with stat1 in esophageal squamous cell carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"B163","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1186\/s12885-018-4539-7","article-title":"Erk is a negative feedback regulator for Ifn-\u0393\/Stat1 signaling by promoting Stat1 ubiquitination","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Cancer"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9274-7","article-title":"Stat1 activation-induced apoptosis of esophageal squamous cell carcinoma cells in vivo","volume":"14","author":"Kaganoi","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s41467-024-45712-2","article-title":"Hkdc1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to Stat1 activation and Pd-L1 expression","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152351","article-title":"Hexokinases in gastrointestinal cancers: from molecular insights to therapeutic opportunities","volume":"52","author":"Liang","year":"2025","journal-title":"Semin Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168755","article-title":"Atorvastatin attenuates programmed death ligand-1 (Pd-L1) induction in human hepatocellular carcinoma cells","volume":"22","author":"Shwe","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03562-9","article-title":"Statins abrogate gemcitabine-induced Pd-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome","volume":"72","author":"Minz","year":"2023","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.707473","article-title":"Tyrosine kinase inhibitors stimulate Hla class I expression by augmenting the Ifn\u03b3\/Stat1 signaling in hepatocellular carcinoma cells","volume":"11","author":"Takahashi","year":"2021","journal-title":"Front Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.02.046","article-title":"Targeting Ese3\/Ehf with nifurtimox inhibits Cxcr2(+) neutrophil infiltration and overcomes pancreatic cancer resistance to chemotherapy and immunotherapy","volume":"167","author":"Xie","year":"2024","journal-title":"Gastroenterology"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.442970","article-title":"Wedelolactone, a naturally occurring coumestan, enhances interferon-\u0393 Signaling through inhibiting Stat1 protein dephosphorylation","volume":"288","author":"Chen","year":"2013","journal-title":"J Biol Chem"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15043","article-title":"Upregulation of Hoxc9 generates interferon-gamma resistance in gastric cancer by inhibiting the Dapk1\/Rig1\/Stat1 axis","volume":"112","author":"Tang","year":"2021","journal-title":"Cancer Sci"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00066-6","article-title":"Cbx3 antagonizes Ifn\u03b3\/Stat1\/Pd-L1 axis to modulate colon inflammation and Crc chemosensitivity","volume":"16","author":"Xiang","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 panda trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"New Engl J Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00274-1","article-title":"Upfront folfoxiri plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (Atezotribe): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01153-4","article-title":"Update on management of squamous cell esophageal cancer","volume":"24","author":"Waters","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082160","article-title":"The pathologic and molecular landscape of esophageal squamous cell carcinogenesis","volume":"12","author":"Businello","year":"2020","journal-title":"Cancers"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"New Engl J Med"},{"key":"B180","doi-asserted-by":"publisher","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, Nccn clinical practice guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (Keynote-590): A randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet (London England)"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.004","article-title":"Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy","volume":"32","author":"Smyth","year":"2021","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","article-title":"Recent developments in immunotherapy for gastrointestinal tract cancers","volume":"17","author":"Chong","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"New Engl J Med"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1948836","article-title":"Emerging data on nivolumab for esophageal squamous cell carcinoma","volume":"15","author":"Hirose","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, Nccn clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (Flot4): A randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet (London England)"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the keynote-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, Nccn clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B191","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1477-2574.2012.00594.x","article-title":"Hepatic resection for hepatocellular carcinoma in patients with child-Pugh\u2019s a cirrhosis: is clinical evidence of portal hypertension a contraindication","volume":"15","author":"Santambrogio","year":"2013","journal-title":"HPB: Off J Int Hepato Pancreato Biliary Assoc"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02473.x","article-title":"General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option","volume":"31","author":"Fujiki","year":"2011","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from imbrave150: atezolizumab plus bevacizumab vs. Sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"Nccn guidelines\u00ae Insights: biliary tract cancers, version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, Nccn clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0029","article-title":"Colon cancer, version 3.2024, Nccn clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0041","article-title":"Nccn guidelines\u00ae Insights: rectal cancer, version 3.2024","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA244","article-title":"Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (Escort-neo): A multi-center, randomized phase Iii trial","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004080","article-title":"Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer","volume":"10","author":"Bai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to Pd-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"B202","article-title":"Pd-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: A single-arm, open-label, phase 2 trial","volume":"11","author":"Sun","year":"2021","journal-title":"Am J Cancer Res"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00736-1","article-title":"Therapeutic landscape and future direction of metastatic colorectal cancer","volume":"20","author":"Bando","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cBiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B205","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"Her2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated Her2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"New Engl J Med"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-Her2 therapeutic antibody Rc48 in patients with Her2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: A single-arm phase Ii study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun (London England)"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy134","article-title":"Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer","volume":"111","author":"Jiang","year":"2019","journal-title":"J Natl Cancer Institute"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X2024e13640","article-title":"Car-T therapy for gastrointestinal cancers: current status, challenges, and future directions","volume":"57","author":"Li","year":"2024","journal-title":"Braz J Med Biol Res = Rev Bras Pesquisas Medicas e Biologicas"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2361","article-title":"Significantly increased anti-tumor activity of carcinoembryonic antigen-specific chimeric antigen receptor T cells in combination with recombinant human Il-12","volume":"8","author":"Chi","year":"2019","journal-title":"Cancer Med"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2022-0081","article-title":"2021 White paper on recent issues in bioanalysis: Tab\/Nab, Viral Vector Cdx, shedding assays; Crispr\/Cas9 & Car-T immunogenicity; Pcr & vaccine assay performance; Ada assay comparability & cut point appropriateness (Part 3 - recommendations on gene therapy, cell therapy, vaccine assays; immunogenicity of biotherapeutics and novel modalities; integrated summary of immunogenicity harmonization)","volume":"14","author":"Loo","year":"2022","journal-title":"Bioanalysis"},{"key":"B212","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting Cd47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.07.062","article-title":"Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion","volume":"24","author":"Liu","year":"2018","journal-title":"Cell Rep"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1604268113","article-title":"Durable antitumor responses to cd47 blockade require adaptive immune stimulation","volume":"113","author":"Sockolosky","year":"2016","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.7150\/thno.79367","article-title":"Blockade of dual immune checkpoint inhibitory signals with a Cd47\/Pd-L1 bispecific antibody for cancer treatment","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics"},{"key":"B216","doi-asserted-by":"publisher","first-page":"eabl9330","DOI":"10.1126\/sciimmunol.abl9330","article-title":"Atr-mediated Cd47 and Pd-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer","volume":"7","author":"Hsieh","year":"2022","journal-title":"Sci Immunol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered Cd47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"key":"B218","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-019-0554-8","article-title":"Hhla2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with Pd-L1","volume":"7","author":"Jing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.984172","article-title":"Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and Hhla2: potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer","volume":"13","author":"Lv","year":"2022","journal-title":"Front Immunol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.11.007","article-title":"Hhla2 Is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival","volume":"442","author":"Yan","year":"2019","journal-title":"Cancer Lett"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25179","article-title":"The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (Hhla2) expression with gastric cancer prognosis","volume":"9","author":"Shimonosono","year":"2018","journal-title":"Oncotarget"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.153911","article-title":"Prognostic values of B7-H3, B7-H4, and Hhla2 expression in human pancreatic cancer tissues based on mihc and spatial distribution analysis","volume":"234","author":"Zhu","year":"2022","journal-title":"Pathol Res Pract"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (Ido) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.593245","article-title":"Malignancy and Ifitm3: friend or foe","volume":"10","author":"Rajapaksa","year":"2020","journal-title":"Front Oncol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12032-024-02308-6","article-title":"Role of interferon-induced transmembrane protein family in cancer progression: A special focus on pancreatic cancer","volume":"41","author":"Wang","year":"2024","journal-title":"Med Oncol (Northwood London England)"},{"key":"B226","doi-asserted-by":"publisher","first-page":"e7431","DOI":"10.1002\/cam4.7431","article-title":"Guanylate binding protein 5 is an immune-related biomarker of oral squamous cell carcinoma: A retrospective prognostic study with bioinformatic analysis","volume":"13","author":"Hasegawa","year":"2024","journal-title":"Cancer Med"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.109892","article-title":"Guanylate binding protein 5 triggers Nf-Kb activation to foster radioresistance, metastatic progression and pd-L1 expression in oral squamous cell carcinoma","volume":"259","author":"Chiu","year":"2024","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15684","article-title":"Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy","volume":"24","author":"Wang","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13010135","article-title":"Alternatively spliced isoforms of Muc4 and Adam12 as biomarkers for colorectal cancer metastasis","volume":"13","author":"Althenayyan","year":"2023","journal-title":"J Personalized Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1598170\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T04:15:03Z","timestamp":1755663303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1598170\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":229,"alternative-id":["10.3389\/fonc.2025.1598170"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1598170","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"1598170"}}